Rhythm Pharmaceuticals, Inc.

RYTM

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001649904

A/B

on the A/B boundary of 369 graded peers in healthcare

rank 80 of 369; percentile 21.5; sampling error 2.5 points; lower is stronger

A B C D E

A/B, the bull



Scoreboard


Profitability	B/C percentile 40.6
Solvency	C percentile 43.9
Growth and financing	B percentile 29.6
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $480.2M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	short runway not computable: fortress balance sheet
Inputs computable	9 of 14
Graded from	filings received through Feb 26, 2026 251 days before the rescan; latest periodic filing 10-Q received Nov 3, 2026
Last close	$86.33 2026-11-03; market equity $6.0B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

We are a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases. We are focused on advancing melanocortin-4 receptor (MC4R) agonists, including our lead asset, IMCIVREE® (setmelanotide), as precision medicines designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 40.6						
Gross profitability	35.5%	32.4%		38.7	365	2025-12-31
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(18.5%)	(6.6%)		23.4	803	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	3.6 pts	2.8 pts		59.8	242	2025-12-31
Solvency, sleeve percentile 43.9						
Twelve-month failure probability	0.06%	0.08%		35.4	247	2026-09-30
Altman Z double-prime	(6.24)	(0.35)		55.2	747	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Current ratio	4.41x	2.92x		41.1	828	2025-12-31
Growth and financing, sleeve percentile 29.6						
Revenue growth, three-year compound	100.2%	10.1%		5.6	412	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 8						
Reinvestment rate	not computable	37.1%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	7.9%	2.2%		34.9	697	2025-12-31
Net share issuance, one year	8.0%	2.5%		48.3	632	2026-02-24


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 5.9 months

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
75	Alpha PRO Tech Ltd. (APT)	20.1	A/B	
76	Boston Scientific Corp. (BSX)	20.4	A/B	
77	Axogen, Inc. (AXGN)	20.7	A/B	
78	Zoetis Inc. (ZTS)	20.9	A/B	
79	Siga Technologies Inc. (SIGA)	21.2	A/B	fortress balance sheet
80	Rhythm Pharmaceuticals, Inc. (RYTM)	21.5	A/B	short runway
81	West Pharmaceutical Services Inc. (WST)	21.7	A/B	fortress balance sheet
82	Axsome Therapeutics, Inc. (AXSM)	22.0	A/B	
83	Rigel Pharmaceuticals Inc. (RIGL)	22.3	A/B	
84	Halozyme Therapeutics, Inc. (HALO)	22.6	B	
85	Lineage Cell Therapeutics, Inc. (LCTX)	22.8	B	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-03 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(16.3%)	(2.2%)	40
Distance from 52-week high	(26.5%)	(29.8%)	54
EBIT to enterprise value	(3.2%)	(1.5%)	45
Free cash flow yield	(1.9%)	(0.9%)	48
Book value to price	0.01	0.28	14
Sales to price	0.03	0.30	11
Composite equity issuance, five years	32.3%	20.5%	59
Relative strength against the sector, log excess return	(0.35)	(0.19)	40

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 6 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$40.0M
Operating cash flow, four quarters	-$81.8M
Months of runway	5.9
Days since last periodic filing	1 (10-Q received Nov 3, 2026)
Median daily dollar volume, 63 sessions	$60.1M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$189.8M	2025-12-31	2026-02-26	10-K	26-012399
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$19.5M	2025-12-31	2026-02-26	10-K	26-012399
3	assets	us-gaap:Assets	$480.2M	2025-12-31	2026-02-26	10-K	26-012399
4	net income	us-gaap:NetIncomeLoss	-$196.5M	2025-12-31	2026-02-26	10-K	26-012399
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$115.7M	2025-12-31	2026-02-26	10-K	26-012399
6	assets	us-gaap:Assets	$392.3M	2024-12-31	2026-02-26	10-K	26-012399
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$130.1M	2024-12-31	2026-02-26	10-K	26-012399
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$13.4M	2024-12-31	2026-02-26	10-K	26-012399
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$77.4M	2023-12-31	2026-02-26	10-K	26-012399
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$9.3M	2023-12-31	2026-02-26	10-K	26-012399
11	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$23.6M	2022-12-31	2024-02-29	10-K	24-002181
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$2.1M	2022-12-31	2025-02-28	10-K	25-001889
13	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$3.2M	2021-12-31	2024-02-29	10-K	24-002181
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$599,000	2021-12-31	2024-02-29	10-K	24-002181
15	current assets	us-gaap:AssetsCurrent	$466.9M	2025-12-31	2026-02-26	10-K	26-012399
16	current liabilities	us-gaap:LiabilitiesCurrent	$105.9M	2025-12-31	2026-02-26	10-K	26-012399
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.4B	2025-12-31	2026-02-26	10-K	26-012399
18	operating income	us-gaap:OperatingIncomeLoss	-$192.0M	2025-12-31	2026-02-26	10-K	26-012399

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	book equity	us-gaap:StockholdersEquity	$139.1M	2025-12-31	2026-02-26	10-K	26-012399
20	liabilities	us-gaap:Liabilities	$210.2M	2025-12-31	2026-02-26	10-K	26-012399
21	operating income	us-gaap:OperatingIncomeLoss	-$184.4M	2023-12-31	2026-02-26	10-K	26-012399
22	interest expense	us-gaap:InterestExpense	$13.9M	2023-12-31	2024-02-29	10-K	24-002181
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$953,000	2025-12-31	2026-02-26	10-K	26-012399
24	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$500,000	2025-12-31	2026-02-26	10-K	26-012399
25	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$196.0M	2025-12-31	2026-02-26	10-K	26-012399
26	income tax	us-gaap:IncomeTaxExpenseBenefit	$497,000	2025-12-31	2026-02-26	10-K	26-012399
27	current assets	us-gaap:AssetsCurrent	$374.2M	2024-12-31	2026-02-26	10-K	26-012399
28	current liabilities	us-gaap:LiabilitiesCurrent	$115.5M	2024-12-31	2026-02-26	10-K	26-012399
29	assets	us-gaap:Assets	$332.7M	2023-12-31	2025-02-28	10-K	25-001889
30	assets	us-gaap:Assets	$382.5M	2022-12-31	2024-02-29	10-K	24-002181
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	68,285,039	2026-02-24	2026-02-26	10-K	26-012399
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	63,223,727	2025-02-24	2025-02-28	10-K	25-001889

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.